Αρχική World News Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung Cancer

Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung Cancer

Sintilimab provided superior clinical benefit compared to docetaxel in patients with previously treated advanced and/or metastatic squamous non-small cell lung cancer (sqNSCLC), according to phase III study findings presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020.

Yuankai Shi of the Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College in Beijing, China presented results from the phase III ORIENT-3 study (NCT03150875), which evaluated the efficacy and safety of sintilimab compared with docetaxel as second-line treatment in sqNSCLC. Sintilimab is a monoclonal antibody targeting the programmed-death-receptor-1 (PD-1).

The study enrolled patients with stage IIIB/IIIC or IV sqNSCLC who were ineligible for radical chemo-radiotherapy and had failed first-line platinum-based chemotherapy. Following 1:1 randomisation, 145 patients received sintilimab at 200 mg and 145 received docetaxel at 75 mg/m2; both agents were delivered intravenously every 3 weeks until disease progression or intolerable toxicity. In addition, patients were stratified according to ECOG performance score of 0 versus 1. The patients’ baseline characteristics were well balanced between treatment groups, with the majority (75.9% versus 77.0% in the sintilimab versus docetaxel arms, respectively) having an ECOG performance score of 1.

Overall survival (OS) served as the primary study endpoint.

Second-line sintilimab showed greater clinical benefit than docetaxel

As of 31 July 2020, a median of 8.0 cycles of sintilimab (range, 1 to 45) and 2.0 cycles of docetaxel (range, 1 to 15) had been administered. The efficacy analysis comprised 280 patients in the full analysis set (FAS), 10 patients in the docetaxel arm were excluded from FAS due to initiation of immunotherapy before receiving docetaxel treatment or before radiographic disease progression on study treatment.

With a median of 23.56 months, the patients treated with sintilimab demonstrated improved OS compared to docetaxel; median OS was 11.79 months (95% confidence interval [CI] 10.28-15.57) versus 8.25 months (95% CI 6.47-9.82) respectively (hazard ratio [HR] 0.74; 95% CI 0.56-0.96; p = 0.02489).

The median progression-free survival (PFS) was significantly prolonged, with 4.30 months (95% CI 4.04-5.78) in sintilimab group compared to 2.79 months (95% CI 1.91-3.19) in docetaxel group (HR 0.52; 95% CI 0.39-0.68; p < 0.00001).

Second-line-Sintilimab-Improves-Survival-Over-Docetaxel-in-Squamous-Non-Small-Cell-Lung-Cancer

Overall survival and progression-free survival in the ORIENT-3 study.

© Yuankai Shi.

The response was more than 5-fold higher with sintilimab, where the objective response rate was 27.6 % (95% CI 20.5-35.6) compared to 5.2% (95% CI 2.1-10.4) with docetaxel.

The safety analysis was done in the safety set of 274 patients (n=144 in sintiliamb arm, n=130 in docetaxel) and revealed a similar prevalence of adverse events (AEs) in the treatment arms; 84.7% of patients on sintilimab and 83.1% of patients receiving docetaxel reported treatment-related AEs (TRAEs). TRAEs ≥ grade 3 occurred at half the frequency with sintilimab versus docetaxel (18.1% versus 36.2%, respectively).

Conclusions

Based upon these findings, the authors were able to conclude that sintilimab as second-line treatment for advanced/metastatic sqNSCLC provided superior OS and PFS as compared with docetaxel.

Funding for this study was reported from Innovent Biologics, Inc. and Eli Lilly and Company.

Reference

30MO – Shi Y, Wu L, Yu X, et al. ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC). ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում

«Քաղցկեղն իմ համայնքում»-ը Cancer.Net Blog շարքից է, որը ցույց է տալիս աշխարհում քաղցկեղի ազդեցությունը և թե ինչպես են մարդիկ աշխատում իրենց տարածաշրջանում քաղցկեղով մարդկանց...

Ovarian cancer screening trial did not save lives

“The effort from the start was to save lives of women with ovarian cancer. To build evidence for a screening programme that the NHS...

Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma

Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after...

Expressive Writing, What is It?

One of psychotherapy’s main beliefs is that putting thoughts and feelings into words may produce mental health benefits. Of course, this also applies to cancer...

Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer

May 12, 2021, by NCI Staff In triple-negative breast cancer (TNBC), tumor cells don't have estrogen receptors (ER), progesterone receptors (PR), or large amounts of...

‘Will cancer make me infertile?’ – That Cancer Conversation

For the first episode of That Cancer Conversation, we explore infertility and cancer. From teenage body worries to an intercontinental surrogacy story, we chat to...